Moderna climbs on full FDA nod for COVID shot in children 6 months or older

Shares of vaccine maker Moderna MRNA.O rise 1.4% to $33.31 premarket

MRNA says U.S. FDA approved its COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease

Co expects the updated shot to be available for eligible populations in the U.S. for the 2025-26 respiratory virus season

Up to last close, stock down 21.1% YTD